

**ASX ANNOUNCEMENT**

22 April 2026

## Notification of Sale of Shares by Director

**Clarity Pharmaceuticals** (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, advises that Managing Director, Michelle Parker has sold 360,896 shares on 20<sup>th</sup> April 2026 with the purpose of funding a tax liability arising from the exercise of share options in Clarity.

Ms Parker advises that the sale was a one-off transaction, and no further sales are planned. Ms Parker remains committed to maintaining a significant long-term shareholding in the Company.

An Appendix 3Y – Change of Director’s Interest Notice is appended to this announcement.

### About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)

### For more information, please contact:

**Clarity Pharmaceuticals**  
Dr Alan Taylor  
**Executive Chairperson**  
[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

Lisa Sadetskaya  
**Director, Corporate Communications**  
[lisa@claritypharm.com](mailto:lisa@claritypharm.com)

*This announcement has been authorised for release by the Executive Chairperson.*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Clarity Pharmaceuticals Ltd</b>
<b>ABN</b>	<b>36 143 005 341</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michelle Parker
<b>Date of last notice</b>	28 November 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	n/a
<b>Date of change</b>	20 April 2026
<b>No. of securities held prior to change:</b>	<ul style="list-style-type: none"> <li>• 1,373,896 fully paid ordinary shares</li> <li>• 316,868 options exercisable at \$0.508 each on or before 01 July 2027</li> <li>• 270,279 options exercisable at \$0.79 each on or before 01 July 2028</li> <li>• 66,089 options exercisable at \$5.505 each on or before 01 July 2029</li> <li>• 20,987 options exercisable at \$8.7703 each on or before 20 November 2029</li> <li>• 151,369 options exercisable at \$7.973 each on or before 20 November 2029</li> <li>• 511,810 options exercisable at \$2.30 each on or before 1 July 2030</li> </ul>

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	N/A
<b>Number disposed</b>	360,896
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$3.0555 per share
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 1,013,000 fully paid ordinary shares</li> <li>• 316,868 options exercisable at \$0.508 each on or before 01 July 2027</li> <li>• 270,279 options exercisable at \$0.79 each on or before 01 July 2028</li> <li>• 66,089 options exercisable at \$5.505 each on or before 01 July 2029</li> <li>• 20,987 options exercisable at \$8.7703 each on or before 20 November 2029</li> <li>• 151,369 options exercisable at \$7.973 each on or before 20 November 2029</li> <li>• 511,810 options exercisable at \$2.30 each on or before 1 July 2030</li> </ul>
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	On market trade

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
<b>Interest acquired</b>	n/a
<b>Interest disposed</b>	n/a

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---

+ See chapter 19 for defined terms.